COTA Research Showcased High Concordance Rate Between Real-World Physician Response Assessment & the 2017 European LeukemiaNet (ELN) Criteria for Acute Myeloid Leukemia at EHA2022
COTA researchers and collaborators’s recent abstract in the European Hematology Association’s library, found that overall agreement between response categories was 65.1% among AML data.
After two years, COTA was back together in NYC for an in-person all-hands meeting. As much as we have learned to adapt to the world of remote work, there is no substitute for the connection, collaboration, and energy that comes from physically being in the same space.
Miami Cancer Institute Takes Action To Address Inequities in Cancer Care with Expanded COTA, Inc. Collaboration
Miami Cancer Institute, part of Baptist Health South Florida, will leverage COTA’s Real-World Analytics to drive standardization of care across all cancer patients
ViVE 2022 brought together thought leaders addressing key disparities and the future of healthcare. Our own C.K. Wang, alongside expert oncologists and technology innovators stressed the need for understanding what “precision oncology” really is.
In this article in the scientific journal Blood Reviews, COTA researchers and collaborators share their views on the many sources of RWD and how to assess fit-for-purpose for use in RWE generation. They also review promising use cases for RWD, particularly for hematologic malignancies.
Working with the FDA and now COTA Laura describes why real-world data is an integral part of today’s patient care.
Diversity in clinical trials is a change that needs to be made in order to make all efforts more efficient and develop a better ending result for patients. Karla Feghali and Laura Fernandes detail why this is so necessary moving forwards.
RWD can help us address one of the most challenging systemic issues in healthcare: disparities in health outcomes perpetuated by uneven access to services and the unconscious bias of humans and technology
This will be the year that patient centricity drives drug development and care delivery decisions.
COTA Collaborates with University of Chicago Medicine and UT Southwestern on Research To Be Presented at the American Society for Hematology’s Annual Meeting & Exposition
Four abstracts will be showcased at the American Society for Hematology’s (ASH) Annual Meeting & Exposition from December 11–14, 2021, in Atlanta, Georgia. COTA has the most comprehensive hematology oncology real-world data that is curated under the close guidance of leading oncologists and hematology specialists.